GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004603410 | Cervix | CC | ATP metabolic process | 90/2311 | 277/18723 | 7.90e-19 | 2.36e-15 | 90 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:00975817 | Cervix | CC | lamellipodium organization | 31/2311 | 90/18723 | 4.57e-08 | 2.76e-06 | 31 |
GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
GO:00300325 | Cervix | CC | lamellipodium assembly | 26/2311 | 72/18723 | 1.87e-07 | 8.48e-06 | 26 |
GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
GO:004593610 | Cervix | CC | negative regulation of phosphate metabolic process | 88/2311 | 441/18723 | 2.92e-06 | 8.27e-05 | 88 |
GO:001056310 | Cervix | CC | negative regulation of phosphorus metabolic process | 88/2311 | 442/18723 | 3.21e-06 | 8.77e-05 | 88 |
GO:00616148 | Cervix | CC | pri-miRNA transcription by RNA polymerase II | 20/2311 | 55/18723 | 4.22e-06 | 1.09e-04 | 20 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
GO:00712148 | Cervix | CC | cellular response to abiotic stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:01040048 | Cervix | CC | cellular response to environmental stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:004232610 | Cervix | CC | negative regulation of phosphorylation | 77/2311 | 385/18723 | 1.09e-05 | 2.38e-04 | 77 |
GO:19027437 | Cervix | CC | regulation of lamellipodium organization | 19/2311 | 54/18723 | 1.27e-05 | 2.60e-04 | 19 |
GO:19028938 | Cervix | CC | regulation of pri-miRNA transcription by RNA polymerase II | 19/2311 | 54/18723 | 1.27e-05 | 2.60e-04 | 19 |
GO:00346129 | Cervix | CC | response to tumor necrosis factor | 55/2311 | 253/18723 | 1.75e-05 | 3.32e-04 | 55 |
GO:00713569 | Cervix | CC | cellular response to tumor necrosis factor | 51/2311 | 229/18723 | 1.75e-05 | 3.32e-04 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HDAC4 | SNV | Missense_Mutation | novel | c.1009G>A | p.Glu337Lys | p.E337K | P56524 | protein_coding | deleterious(0.01) | benign(0.231) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
HDAC4 | SNV | Missense_Mutation | rs753482334 | c.2238N>A | p.Phe746Leu | p.F746L | P56524 | protein_coding | deleterious(0.01) | benign(0.207) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
HDAC4 | SNV | Missense_Mutation | | c.2610N>G | p.Phe870Leu | p.F870L | P56524 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HDAC4 | SNV | Missense_Mutation | novel | c.1132N>G | p.Leu378Val | p.L378V | P56524 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
HDAC4 | SNV | Missense_Mutation | | c.2306G>A | p.Gly769Glu | p.G769E | P56524 | protein_coding | deleterious(0.02) | benign(0.221) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HDAC4 | deletion | Frame_Shift_Del | novel | c.887_909delNNNNNNNNNNNNNNNNNNNNNNN | p.Pro296GlnfsTer228 | p.P296Qfs*228 | P56524 | protein_coding | | | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
HDAC4 | deletion | Frame_Shift_Del | novel | c.2626delG | p.Ala876LeufsTer81 | p.A876Lfs*81 | P56524 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
HDAC4 | SNV | Missense_Mutation | novel | c.1090N>C | p.Ser364Pro | p.S364P | P56524 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
HDAC4 | SNV | Missense_Mutation | rs745953691 | c.412N>T | p.Arg138Cys | p.R138C | P56524 | protein_coding | deleterious(0.02) | possibly_damaging(0.751) | TCGA-DG-A2KH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HDAC4 | SNV | Missense_Mutation | rs753482334 | c.2238N>A | p.Phe746Leu | p.F746L | P56524 | protein_coding | deleterious(0.01) | benign(0.207) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 187051793 | GIVINOSTAT | |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | inhibitor | VALPROIC ACID | DEPAKOTE | |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565599 | | |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | | PMID29671355-Compound-71a | | |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | | PMID29671355-Compound-43 | | |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | | PMID29671355-Compound-31 | | |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | | LARGAZOLE | LARGAZOLE | 21420302,25203782,20491440 |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | | PHENYLBUTANOIC ACID | PHENYLBUTANOIC ACID | 24044874 |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL3545052 | FIMEPINOSTAT | |
9759 | HDAC4 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL598797 | CUDC-101 | |